World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
23439
World Ranking
18004
National Ranking
8975

Stephen C. Rubin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stephen C. Rubin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 324 publications — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stephen C. Rubin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stephen C. Rubin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Stephen C. Rubin is affiliated with the University of Pennsylvania in the United States. Their research primarily focuses on medicine, with a particular emphasis on oncology, reproductive medicine, pulmonary and respiratory medicine, surgery, and cardiology and cardiovascular medicine.

The scientist has contributed extensively to the study of ovarian cancer diagnosis and treatment, cardiac, anesthesia and surgical outcomes, renal cell carcinoma treatment, endometrial and cervical cancer treatments, pancreatic and hepatic oncology research, anesthesia and pain management, as well as spine and intervertebral disc pathology.

Frequent co-authors include Christina Chu, Krishnansu S. Tewari, Bradley J. Monk, Joan L. Walker, and Kristin Bixel.

Common publication venues for their work include:

  • Gynecologic Oncology
  • International Journal of Gynecological Cancer
  • Annals of Surgery
  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries

Among their recent papers are:

  • Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program (2020), International Journal of Gynecological Cancer
  • Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study (2020), Gynecologic Oncology
  • Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study (2021), Gynecologic Oncology
  • A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery (2024), Annals of Surgery
  • Lymph node dissection at the time of hysterectomy for uterine cancer is associated with venous thromboembolism: An analysis of the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database (2020), Gynecologic Oncology

Best Publications

  • Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

    Lin Zhang;Jose R. Conejo-Garcia;Dionyssios Katsaros;Phyllis A. Gimotty

  • Regulatory CD4+CD25+ T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer

    Edward Y. Woo;Christina S. Chu;Theresa J. Goletz;Katia Schlienger

  • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

    M Markman;R Rothman;T Hakes;B Reichman

  • Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    Robert L. Coleman;Mark F. Brady;Thomas J. Herzog;Paul Sabbatini

  • Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1

    Stephen C. Rubin;Ivor Benjamin;Kian Behbakht;Hiroyuki Takahashi

  • Secondary surgical cytoreduction for advanced ovarian carcinoma

    Peter G Rose;Stacy Nerenstone;Stacy Nerenstone;Mark F Brady;Daniel Clarke-Pearson

  • Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Michael J. Sundborg

  • Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

    M Markman;E Rowinsky;T Hakes;B Reichman

  • Tumor-derived Vascular Endothelial Growth Factor Up-Regulates Angiopoietin-2 in Host Endothelium and Destabilizes Host Vasculature, Supporting Angiogenesis in Ovarian Cancer

    Lin Zhang;Nuo Yang;Jin-Wan Park;Dionyssios Katsaros

  • Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

    Maurie Markman;John Blessing;Stephen C. Rubin;Joseph Connor

  • Mutation Analysis of the BRCA1 Gene in Ovarian Cancers

    Hiroyuki Takahashi;Kian Behbakht;Patricia E. McGovern;Hsiu Chiang Chiu

  • Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

    M Markman;B Reichman;T Hakes;W Jones

  • Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

    Kian Behbakht;Michael W. Sill;Michael W. Sill;Kathleen M. Darcy;Stephen C. Rubin

  • Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer.

    Lin Zhang;Nuo Yang;Alisha Mohamed-Hadley;Stephen C Rubin

  • BRCA1, BRCA2, and Hereditary Nonpolyposis Colorectal Cancer Gene Mutations in an Unselected Ovarian Cancer Population: Relationship to Family History and Implications for Genetic Testing

    Stephen C. Rubin;M. Anne Blackwood;Christina Bandera;Kian Behbakht

  • Vascular leukocytes contribute to tumor vascularization.

    Jose R. Conejo-Garcia;Ronald J. Buckanovich;Fabian Benencia;Maria C. Courreges

  • Prevalence and Predictors of Psychological Distress Among Women With Ovarian Cancer

    Tina R. Norton;Sharon L. Manne;Stephen Rubin;John Carlson

  • Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

    Joan L. Walker;Mark F. Brady;Lari Wenzel;Gini F. Fleming

  • Treatment of endometrial stromal tumors

    Andrew Berchuck;Stephen C. Rubin;William J. Hoskins;Patricia E. Saigo

  • Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.

    Stephen C. Rubin;Thomas C. Randall;Katrina A. Armstrong;Dennis S. Chi

Frequent Co-Authors

William J. Hoskins
William J. Hoskins Memorial Sloan Kettering Cancer Center
Maurie Markman
Maurie Markman The University of Texas MD Anderson Cancer Center
George Coukos
George Coukos Cornell University
Richard R. Barakat
Richard R. Barakat Northwell Health
Kenneth O. Lloyd
Kenneth O. Lloyd Memorial Sloan Kettering Cancer Center
Lin Zhang
Lin Zhang University of Pennsylvania
Robert S. Mannel
Robert S. Mannel University of Oklahoma Health Sciences Center
Sharon L. Manne
Sharon L. Manne Rutgers, The State University of New Jersey
Phyllis A. Gimotty
Phyllis A. Gimotty University of Pennsylvania
Virginia A. LiVolsi
Virginia A. LiVolsi University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA is highly competitive and rigorous, prospective healthcare professionals have alternative pathways to build their careers. Online nursing programs offer flexible, accredited options for students seeking practical, in-demand healthcare roles.

For those looking to start their nursing journey or advance their credentials, a nursing degree online provides a convenient and often more affordable entry point. Registered nurses aiming to expand their skills and earning potential can pursue cheap rn to bsn online programs, designed to fit around busy work schedules.

For non-nurses or career changers, cheapest direct entry msn programs allow individuals with a non-nursing bachelor’s degree to become nurses with a master’s qualification in an accelerated timeframe. Practicing nurses aiming to reach the highest clinical positions may consider the cheapest online dnp programs for terminal professional degrees.

These online degrees create flexible and cost-effective career pathways, helping students unlock new opportunities in healthcare without the traditional roadblocks of location, time, or steep tuition costs.

Best Scientists Citing Stephen C. Rubin

Trending Scientists

Recently Published Articles